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Patterns of Retinoblastoma in Zimbabwe: 2000-2009
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Abstract
Objective: To document the pattern o f retinoblastoma in children in Zimbabwe for the period 2000-2009. 
D esign: Retrospective study.
M ethods: Analysis o f  data from the Zimbabwe National Cancer registry and records o f patients admitted to 
the Paediatric Oncology unit. Data collected from cancer registry were basis o f diagnosis, age and gender. 
Data from the patients medical records included clinical presentation, time to diagnosis and treatment. 
Settings : The Zimbabwe National Cancer Registry and Paediatric Oncology Unit at Parirenyatwa Tertiary 
Hospital.
Results: 196 patients with retinoblastoma were registered at the cancer registry over the study period. The 
diagnosis was confirmed histologically on 89% o f the cases and in 7% the diagnosis was based on clinical 
grounds. The age ranged from less than one month to 7 years with median age o f 24 months. Males were 111 ( 
56%) with male:female ratio o f 1.3:1. Forty three patients ( 84%) had unilateral and 8 ( 16%) bilateral 
disease. Medical records were retrieved from only 54 /196 cases (27.5%). The commonest clinical 
presentation was proptosis 35/54 (65% ). Leucocoria was present in 14/54 (26%). Time interval between first 
symptoms and diagnosis ranged from less than one month to 24 months with mean duration o f  7.7 months ( 
SD=6.9). Enucleation was performed on 33/ 54 ( 61%), exenteration on 20/54 ( 37%) chemotherapy was 
given to 34/54 (63% ) and only 6/54 ( 11%) received radiotherapy.
Conclusion: Retinoblastoma is the third commonest registered malignancy o f childhood in Zimbabwe, 
characaterised by late presentation and poor access to therapy.
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Introduction
Retinoblastoma is the most common intraocular 
malignant tumour of childhood but it remains a rare 
disease.1 It occurs more commonly in less affluent 
regions of the world compared to richer regions. The 
incidence of retinoblastoma within age group 0-4 years 
varies from country to country. Africa generally has a 
higher incidence especially in the sub Saharan Africa 
region ranging from 10.6 to 42.5cases per million. This 
is in contrast to developed countries where in the USA,
the incidence is 11.8 and in Europe it ranges from 6-12. 
Bulgaria has the lowest incidence of 3.4 cases per 
million."' In Zimbabwe the incidence of retinoblastoma 
is estimated at 23.3 per million ranking 3rd highest in the 
world after Uganda and Mali.4
The mode of presentation varies between countries 
with leucocoria being the commonest presentation in 
developed countries' and proptosis being common in 
developing countries.” Late presentation is a feature 
in many developing countries accounting for the poor 
outcome.610 The trend in management for early
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presentation is for conservative local treatment with 
preservation of vision.13 However in developing 
countries where majority present late with advanced 
disease, enucleation remains a common form of
. , . 8.14.15treatment.
Over 95% of children with retinoblastoma in the 
United States and other medically developed nations 
survive their malignancy due largely to early detection 
when the tumour is contained in the eye.1’ In 
developing nations, the survival is much less with late 
presentation, poor treatment compliance and limited 
treatment options being the major causes for these poor 
results.16
The purpose of this study is to document the pattern of 
presentation of children in Zimbabwe diagnosed with 
retinoblastoma over a 10 year period from 2000-2009. 
The findings will help in recommendations for 
improving the management of this condition.
Methods
This was a retrospective analysis of data on children 
diagnosed with retinoblastoma over a 10 year period 
from 2000-2009. Formal approval for the study was 
obtained from the Joint Parirenyatwa Hospital and 
College o f Health Sciences Research Ethics 
Committee. The main source of data for the study was 
collected from the Zimbabwe National Cancer 
Registry. The Cancer Registry follows Standard 
procedures which ensure that only incident cases are 
recorded and that multiple notifications of the same 
cancer have been detected. The Registry methods have 
been described in previous publications.1718 The other 
source of data was from case notes of patients who 
were admitted to the Paediatric Oncology Unit (POU) 
who were mainly referrals from Sekuru Kaguvi Eye 
Unit.
The POU is placed at the Parirenyatwa Teaching 
Hospital and provides cancer treatment for children up 
to 12 years of age. It has a maximum capacity of 15 
cots/beds and occupies a section of a general paediatric 
medical ward.
Children seen at Sekuru Kaguvi Eye Unit with 
diagnosis of Retinoblastoma are referred to POU for 
chemotherapy.
The information collected from the case notes of 
patients admitted to POU were the clinical 
presentation, time to diagnosis and treatment.
Statistical methods.
Data was entered into EPIINFO soft ware for analysis. 
Statistical methods used were those for descriptive 
studies. Median with Q1 and Q3 was calculated for 
age. Mean, SD, and 95% confidence interval (Cl) were 
calculated for the time to diagnosis. P value of <0.05 
was taken as statistically significant.
Results
A total of 196 cases of retinoblastoma were registered
in the Zimbabwe National Cancer Registry from 
January 2000 to December 2009. All these children 
were below 15 years of age. During the same period of 
time a total of 1766 cases of childhood malignancies 
below 15 years of age were registered in the cancer 
registry, with retinoblastoma accounting for 13 % of all 
malignancies in children registered in Zimbabwe.
The diagnosis of retinoblastoma was confirmed on 
histology in 89% of the cases and in 7% the diagnosis 
was based on clinical grounds. In 4% of the cases there 
was no record on how the diagnosis was made.
Of the 196 registered retinoblastoma cases, medical 
records could be retrieved for only 54 cases (27.5%).
Age at presentation.
The ages of the children ranged from less than one 
month to 7 years of age with a median age of 24 months 
(Q1 = 2 0  months and Q3= 36 months). Ninety five 
percent of the children were 5 years of age or below and 
58% were 2 years or below.
Gender.
There were 111 males and 85 females giving a male: 
female ratio of 1.3:1. There was no statistically 
significant age difference between the gender groups 
(p=0.489).
Clinicalpresentation.
Data on clinical presentation was available on 51 
patients. Of these, the majority of patients, 43 (84%) 
had unilateral disease and 8 (16.0%) had bilateral 
disease. The median age of children with unilateral 
disease was 36 months (Ql=24, Q3=48) and bilateral 
23.5 months (Q l= l7.5 and Q3=30.5). There was no 
difference in gender distribution between the two 
groups.
The commonest clinical presentation in our 
experience was proptosis35/54 (65%) and leucocoria 
14/54 (26%). There were no cases of strabismus.
Time to diagnosis.
The time interval between first symptoms and 
diagnosis ranged between less than one month to 24 
months with mean duration of symptoms of 7.7 months 
(SD=6.9).
Treatment.
The majority of patients 33/54 (61%) had enucleation 
and 20 /54 (37%) had exenteration. Chemo therapy 
was given to 34/54 (63%) of the cases. At the time of the 
study, the chemotherapy regimen used was Vincristine, 
Doxorubicin and cyclophosphamide for 6-8 courses. 
Only 6/54 patients (11 %) received radiotherapy.
Discussion
Of the total of 1766 malignancies registered in children 
under 15 years during the period of the study, 
retinoblastoma accounted for 13% and ranked third 
most common malignancy after Wilm's tumour 17 %
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and Kaposi Sarcoma 15.7%. The relatively high 
frequency of retinoblastoma seen in our series is 
similar to reports from researchers in developing 
countries with Tanzania 12.9%, Malawi 11.3% and 
Nigeria 8%.9 20 21 This high frequency of retinoblastoma 
is in contrast to developed countries where 
retinoblastoma represents only 3% of all malignant 
tumours in children.22
The diagnosis of retinoblastoma was confirmed on 
histology in 89% of the cases and in only 7% was the 
diagnosis made on clinical grounds. The rate of 
histological confirmation in our series was very high 
compared to reports from East Africa where only 35% 
of the diagnosis was based on histology and the rest on 
clinical grounds.19 In Nigeria, histology was performed 
in only 3 cases out of a series of 13 children seen over a 
10 year period.14
Age at presentation.
Almost all patients in our study (96%) were aged 5 
years and below with a median age of 24 months which 
although lower than that reported in other developing 
countries6"1*15 is still higher than 19 months reported in 
developed countries such as the UK.2' The late 
presentation of retinoblastoma commonly reported in 
low income countries is often attributed to poor 
awareness of presenting signs of retinoblastoma, low 
parental education and limited access to health care 
services.22
Gender.
Although various studies reveal no significant 
differences between males and females'5"426 in our 
series although not significant, there was a slight 
predilection to males with M:F ratio of 1.3:1 which is 
similar to 1.4:1 reported in Uganda.4 In Mali7 which has 
the highest incidence of Retinoblastoma in the world,4 
the male:female ratio was 2:1. The gender distribution 
is in marked contrast to that reported in Native Alaska 6 
where retinoblastoma is much higher in girls than in 
boys with male: female ratio of 1:3.
Of the 196 cases registered only 54 patients (27.5%) 
were able to access chemotherapy at the Tertiary 
Hospital. The majority of our patients with 
Retinoblastoma do not have access to chemotherapy 
and therefore remain untreated with fatal outcome. 
This poor access to treatment of retinoblastoma is 
common in developing countries.16 In East Africa 
researchers reported only 18% of their patients with 
retinoblastoma having access to treatment.19
Clinical presentation.
The incidence of bilateral retinoblastoma in our 
patients is 16%. This compares well with findings from 
other African series14 whereas the incidence of 
bilateral disease is much higher in Western 
countries.24 27 The median age at presentation of 
bilateral disease in our patients is 23.5 months much 
younger compared to 36 months in our patients with 
unilateral disease (84%). The younger age of bilateral
disease at presentation compared to unilateral disease 
is widely reported in other countries in Africa,6 7 '4 
Asia1012 and in Western countries5 28 although the mean 
ages of presentation is lower in both unilateral and 
bilateral diseases in Western countries. In Japan, over 
the years there has been a decrease in mean ages at 
presentation in both unilateral and bilateral disease and 
that was attributed to increased parental knowledge and 
advances in diagnostic modalities.29
In our study, the majority of our patients 35/54 (65%) 
presented with propotosis whilst 14/54 (26%) 
presented with leucocoria. Proptosis is a common 
presentation of retinoblastoma in developing countries 
and is due to late presentation and diagnosis. In a study 
in Mali,7 among 55 patients with retinoblastoma, 54% 
presented with exophthalmous followed by leucocoria 
38.2%. Similarly in Nepal,"140.42 % presented with 
proptosis followed by leucokoria in 29.78 % of cases. 
This is in contrast to that reported in developed 
countries such as Great Britain28 where leucocoria was 
the commonest presentation in 50% followed by squint 
25%. The differences in presentation is not only 
confined to developed and developing countries but 
even within the same country but in different regions 
there are also differences in presentation. Owoeye et 
a /15 from Ilorin, West Central part of Nigeria found 
proptosis to be the commonest presentation accounting 
for 84.6% of the cases compared to another region in 
the South of Nigeria'4 where only 15.4% of patients 
presented with extra ocular retinoblastoma and the 
majority 61.5% presented with leucocoria.
Time to diagnosis.
The mean time to diagnosis (duration of symptoms 
reported by parents prior to diagnosis) in our study was 
7 months which is much longer than 8 weeks reported 
by researchers in the UK.25 In developing countries in 
Africa814 and Asia"’ 12 the mean time to diagnosis is 
longer than in developed countries.24 5 30 Researches 
from Brazil31 and Argentina22 have noted that children 
with a longer period of time to diagnosis of disease 
were more likely to have more clinically advanced 
disease. In Mali7 the delay in presentation was 
attributed to factors such as patients moving from one 
traditional healer to another, and to lack of knowledge 
among social health workers and doctors about the 
early signs of the disease. Our experience concerning 
delays in health seeking behavior is pretty much similar 
to that above.
Treatment.
The approach to treatment of Retinoblastoma in our 
centre includes, enucleation, exenteration and systemic 
chemotherapy. Eye conserving treatment is not usually 
offered because our patients present late with advanced 
disease. In many developing countries where a 
multimodal approach is not available, enucleation is 
the most common treatment option.8'""4'15
In our series, enucleation was performed on 33/54 
(61%) of the patients while 20/54 (37%) had
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exenteration. The rate of enucleation among our 
patients is slightly below the trend o f65-75% reported 
by researchers in the USA’: but higher than the rates 
reported in Mali and Nigeria 14 where the relatively 
lower rates of enucleation were attributed to lack of 
radiotherapy, cultural factors and financial constraints 
by the families unable to meet the cost of enucleation.
Most of our patients 34/54 (63%) were treated 
aggressively with chemotherapy using Vincristine, 
Cyclophosphamide and Doxorubicin. The use of 
chemotherapy among our patients was much higher 
than reported from Nigeria1" where only 3 (15%) had 
chemotherapy and in Tanzania" where only 6% 
received chemotherapy.
In their series of 33 patients with orbital 
retinoblastoma Doz F et al" reported improved 
outcome in their patients who received intensive 
chemotherapy even where there was associated extra 
CNS metastases.
Radiotherapy was not easily available to our patients 
as only 6/54 (11%) had radiotherapy. It is difficult to 
assess the impact lack of radiotherapy has on the 
outcome of our patients. Researchers in Ibadan in 
Nigeria reported improvement in the treatment 
outcome and prognosis of children with retinoblastoma 
who had radiotherapy.'4 In Brazil' combination of 
chemotherapy and radiotherapy is the mainstay in the 
treatment of patients with advanced retinoblastoma.
We do acknowledge a limitation of this study. The 
small numbers of case notes of patients admitted that 
were analysed in comparison to the total numbers of 
cases registered makes it impossible to make 
inferences for the whole population from this series.
Conclusion
Retinoblastoma is the third commonest registered 
malignancy of childhood in Zimbabwe, characaterised 
by late presentation and poor access to therapy. 
Awareness campaigns on signs and symptoms of 
re tin o b las to m a  and its good response  to 
chemotherapeutic agents may assist in early disease 
detection and resource mobilization.
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